RxDoctor Payments Data

Jenn Liu, DO

Ophthalmology · Okemos, MINPI 1609875566

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 106 payments — averaging $12.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$374
  • AbbVie$184
  • Tarsus Pharmaceuticals, Inc.$163
  • Mallinckrodt Hospital Products Inc.$151
  • Oyster Point Pharma, Inc.$111
  • Novartis$89
  • plus $266 from 10 others

What the payments were for

  • Food & beverage$1,15987%
  • Education$18013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,338 in reported general payments places this provider in the 50th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$202,136
Medicare patients
705
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine286$372,337
XiidraLifitegrast132$195,959
Cyclosporine269$144,216
LumiganBimatoprost116$67,933
Travoprost162$38,644
TafluprostTafluprost/Pf107$34,544
Brimonidine Tartrate122$29,010
RocklatanNetarsudil Mesylat/Latanoprost29$26,349
CequaCyclosporine23$26,056
VyzultaLatanoprostene Bunod54$25,789
Latanoprost981$23,314
CombiganBrimonidine Tartrate/Timolol56$22,998
ZioptanTafluprost/Pf34$18,238
Prednisolone Acetate374$17,432
IyuzehLatanoprost/Pf13$10,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$184$466,489471 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo, Zirgan$374$240,577210 claims
Aerie Pharmaceuticals, Inc.Rocklatan$41$26,34929 claims
Sun Pharmaceutical Industries Inc.Cequa$38$26,05623 claims
Thea Pharma Inc.Iyuzeh$25$10,62313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →